Search

Your search keyword '"Raab, M"' showing total 1,130 results

Search Constraints

Start Over You searched for: Author "Raab, M" Remove constraint Author: "Raab, M"
1,130 results on '"Raab, M"'

Search Results

3. Real-world analysis of teclistamab in 123 RRMM patients from Germany

4. Safe liquid scintillators for large scale detectors

14. A dissociable functional relevance of theta- and beta-band activities during complex sensorimotor integration

15. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

16. TRACK: A new algorithm and open-source tool for the analysis of pursuit-tracking sensorimotor integration processes

17. The neurophysiology of continuous action monitoring

18. Forschungsinitiative Energiewende im Verkehr. Kurzbericht zur Roadmap für strombasierte Kraftstoffe

19. Roadmap für strombasierte Kraftstoffe. Gesamtbericht zur Begleitforschung Energiewende im Verkehr (BEniVer)

22. Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myeloma

25. Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma

27. A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3

33. P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA

34. P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL

35. P937: PRECLINICAL DISCOVERY AND EARLY FINDINGS FROM THE PHASE 1, DOSE-ESCALATION STUDY OF WVT078, A BCMA-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH R/R MULTIPLE MYELOMA

37. P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL

38. P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3

41. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

42. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma

45. P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY

Catalog

Books, media, physical & digital resources